Experimental drug duo takes on tough lymphoma
NCT ID NCT06660563
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests two experimental drugs, JNJ-80948543 and JNJ-75348780, given together to people with relapsed or refractory B-cell non-Hodgkin lymphoma. The study involves 19 participants and aims to find the safest dose and check for side effects. It is not yet known if the combination will shrink tumors or improve outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JNJ-80948543 and JNJ-75348780 (two experimental drugs that help the immune system attack cancer cells)
What this could lead to
If successful, this could point toward a new combination treatment option for people with hard-to-treat B-cell non-Hodgkin lymphoma.
What could go wrong
This is a very early Phase 1 trial with only 19 participants, so it is primarily testing safety and dosing. The drugs may cause serious side effects or not work well enough to move forward.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
China Medical University Hospital
Taichung, 40447, Taiwan
-
Concord Hospital
Concord, 2139, Australia
-
Hosp Univ Vall D Hebron
Barcelona, 08035, Spain
-
Hosp. Clinic de Barcelona
Barcelona, 08036, Spain
-
Hosp. Gral. Univ. Gregorio Maranon
Madrid, 28007, Spain
-
Hosp. Univ. 12 de Octubre
Madrid, 28041, Spain
-
Inst. Cat. Doncologia-H Duran I Reynals
L'Hospitalet de Llobregat, 08908, Spain
-
Macquarie University Hospital
North Ryde, 2109, Australia
-
National Taiwan University Hospital
Taipei, 100, Taiwan
-
St Vincents Hospital Melbourne
Fitzroy, 3065, Australia
-
University Hospitals Of Leicester Nhs Trust
Leicester, Le1 5ww, United Kingdom